Clorox (NYSE:CLX) Stock Rating Upgraded by BNP Paribas Exane

Clorox (NYSE:CLX) was upgraded by BNP Paribas Exane from an “underperform” rating to a “neutral” rating in a note issued to investors on Wednesday, MarketBeat Ratings reports.

A number of other analysts also recently issued reports on the stock. Citigroup lifted their price objective on shares of Clorox from $109.00 to $115.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Jefferies Financial Group decreased their target price on shares of Clorox from $152.00 to $151.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Rothschild & Co Redburn cut their price target on shares of Clorox from $120.00 to $115.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Barclays restated an “underweight” rating and set a $109.00 price objective on shares of Clorox in a research note on Friday, January 16th. Finally, Wall Street Zen raised Clorox from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. One equities research analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $117.93.

Clorox Price Performance

CLX stock opened at $124.62 on Wednesday. The stock has a 50-day moving average price of $107.21 and a two-hundred day moving average price of $113.74. The stock has a market cap of $15.07 billion, a PE ratio of 20.36, a price-to-earnings-growth ratio of 0.62 and a beta of 0.59. The company has a current ratio of 0.74, a quick ratio of 0.48 and a debt-to-equity ratio of 71.03. Clorox has a 1 year low of $96.66 and a 1 year high of $159.04.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.39 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.04). The firm had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.64 billion. Clorox had a net margin of 11.17% and a return on equity of 383.01%. The business’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter last year, the firm earned $1.55 earnings per share. Equities analysts forecast that Clorox will post 7.15 EPS for the current fiscal year.

Insider Buying and Selling

In other Clorox news, Director Pierre R. Breber purchased 4,000 shares of the stock in a transaction on Friday, November 21st. The shares were purchased at an average price of $104.13 per share, with a total value of $416,520.00. Following the completion of the transaction, the director directly owned 13,000 shares in the company, valued at $1,353,690. This represents a 44.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.63% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Clorox by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 15,845,496 shares of the company’s stock valued at $1,902,569,000 after acquiring an additional 272,420 shares during the period. State Street Corp increased its holdings in shares of Clorox by 3.5% in the third quarter. State Street Corp now owns 8,434,277 shares of the company’s stock valued at $1,039,946,000 after purchasing an additional 282,794 shares during the last quarter. Invesco Ltd. raised its position in shares of Clorox by 23.1% in the third quarter. Invesco Ltd. now owns 3,995,590 shares of the company’s stock valued at $492,656,000 after purchasing an additional 750,415 shares during the period. Geode Capital Management LLC raised its position in shares of Clorox by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 3,172,233 shares of the company’s stock valued at $318,613,000 after purchasing an additional 10,060 shares during the period. Finally, Van ECK Associates Corp lifted its stake in shares of Clorox by 93.9% during the 3rd quarter. Van ECK Associates Corp now owns 2,709,972 shares of the company’s stock worth $334,139,000 after buying an additional 1,312,471 shares during the last quarter. 78.53% of the stock is currently owned by institutional investors.

Key Headlines Impacting Clorox

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Clorox paid a $1.24 dividend on Feb. 13, continuing a 48‑year streak of consecutive dividend increases — a strong signal for income investors supporting demand for CLX shares. Clorox’s 5% Yield Dominates Consumer Staples: Can It Continue?
• Positive Sentiment: Coverage pieces highlighting Clorox as a high‑yield, dividend-bearing consumer staple have kept investor interest intact despite near‑term headwinds. Consumer Staples Look Pricey. Consider Clorox and Other High Yielders With Solid Dividends.
• Neutral Sentiment: Q2 was mixed — revenue slightly beat estimates but EPS missed; International and Health & Wellness helped offset weakness in Household and Lifestyle, leaving guidance/forward outlook uncertain. Q2 Deep Dive: Evaluating Clorox’s Financial and Operating Metrics
• Neutral Sentiment: Analysts and commentators are debating valuation after the mixed quarter and ongoing ERP and promotion headwinds — some see buying value after a rebound, others see mixed upside. A Look At Clorox’s Valuation After A Mixed Quarter And Ongoing ERP And Promotion Headwinds
• Neutral Sentiment: Sector context: CLX has outperformed several staples peers year‑to‑date, which supports momentum-oriented buyers even as company‑specific risks persist. P&G Rallies Under New CEO but Lags Rivals, Faces Tariff Challenges
• Negative Sentiment: Margin pressure is a recurring theme — analysts warn a margin squeeze could force changes to Clorox’s capital-return mix (buybacks vs. dividend), which is bearish for total-return expectations. Is Clorox’s (CLX) Margin Squeeze Reshaping Its Capital Return Playbook?
• Negative Sentiment: Barclays reaffirmed a sell rating, keeping downside pressure from investor sentiment and potential selling. Barclays Reaffirms Their Sell Rating on Clorox (CLX)
• Negative Sentiment: RBC Capital left a Hold rating in place, another signal of limited near‑term upside from some institutional investors. RBC Capital Sticks to Its Hold Rating for Clorox (CLX)

Clorox Company Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.